Whitehawk Therapeutics Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Whitehawk Therapeutics stock has a target of 7.00, which predicts a 182.83% increase from the current stock price of 2.48.

Price Target: $7.00 (+182.83%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$7.00	$7.00	$7.00	$7.00
Change	+182.83%	+182.83%	+182.83%	+182.83%

Analyst Ratings

According to 1 stock analyst, the rating for Whitehawk Therapeutics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Dec '25
Strong Buy	1
Buy	0
Hold	0
Sell	0
Strong Sell	0
Total	1

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Soumit Roy Jones Trading	Jones Trading	Strong Buy Initiates $7	Strong Buy	Initiates	$7	+182.83%	Dec 22, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

7.27M

from 25.98M

-72.04%

from 25.98M

Revenue Next Year

n/a

from 7.27M

EPS This Year

-0.28

from -2.36

EPS Next Year

-1.40

from -0.28

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	14.58M	1.12M	15.22M	24.35M	25.98M	7.27M	-
Revenue Growth	1,846.60%	-92.32%	1,258.57%	60.06%	6.69%	-72.04%	-
EPS	-1.76	-12.41	-2.69	-2.44	-2.36	-0.28	-1.40
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	5	5

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026
High	7.5M	n/a
Avg	7.3M	n/a
Low	7.0M	n/a

Revenue Growth

Revenue Growth	2025	2026
High	-71.1%	-
Avg	-72.0%	-
Low	-73.2%	-

EPS Forecast

EPS	2025	2026
High	-0.26	-1.22
Avg	-0.28	-1.40
Low	-0.29	-1.62

EPS Growth

EPS Growth	2025	2026
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.